Nomogram to Predict Cycle-One Serious Drug-Related Toxicity in Phase I Oncology Trials von HYMAN, David M, EATON, Anne A, GOUNDER, Mrinal M, SMITH, Gary L, PAMER, Erika G, HENSLEY, Martee L, SPRIGGS, David R, IVY, Percy, IASONOS, Alexia

Volltext

Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities von Eaton, Anne, Iasonos, Alexia, Gounder, Mrinal M, Pamer, Erika G, Drilon, Alexander, Vulih, Diana, Smith, Gary L, Ivy, S Percy, Spriggs, David R, Hyman, David M

Volltext

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials von Hyman, David M, Eaton, Anne A, Gounder, Mrinal M, Pamer, Erika G, Pettiford, Jasmine, Carvajal, Richard D, Ivy, S Percy, Iasonos, Alexia, Spriggs, David R

Volltext

Celecoxib Alters the Intestinal Microbiota and Metabolome in Association with Reducing Polyp Burden von Montrose, David C, Zhou, Xi Kathy, McNally, Erin M, Sue, Erika, Yantiss, Rhonda K, Gross, Steven S, Leve, Nitai D, Karoly, Edward D, Suen, Chen S, Ling, Lilan, Benezra, Robert, Pamer, Eric G, Dannenberg, Andrew J

Volltext

Abstract LB-302: Celecoxib alters the intestinal microbiota and metabolome in association with reducing polyp burden von Montrose, David C., Zhou, Xi K., McNally, Erin M., Sue, Erika, Gross, Steven S., Leve, Nitai D., Karoly, Edward D., Ling, Lilan, Pamer, Eric G., Dannenberg, Andrew J.

Volltext